GSK (LON:GSK) Issues Earnings Results

GSK (LON:GSK) released its earnings results on Wednesday. The company reported GBX 23.20 ($0.29) EPS for the quarter, Digital Look Earnings reports. GSK had a return on equity of 33.30% and a net margin of 12.83%.

GSK Stock Performance

Shares of LON GSK opened at GBX 1,500.50 ($18.76) on Thursday. The stock has a market cap of £61.22 billion, a PE ratio of 1,327.88, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK has a 1 year low of GBX 1,282.50 ($16.03) and a 1 year high of GBX 1,823.50 ($22.80). The firm has a fifty day moving average price of GBX 1,353.92 and a 200-day moving average price of GBX 1,457.61. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73.

Wall Street Analyst Weigh In

GSK has been the subject of several recent analyst reports. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research report on Tuesday, January 7th. Berenberg Bank decreased their target price on shares of GSK from GBX 1,820 ($22.75) to GBX 1,600 ($20.00) and set a “buy” rating for the company in a report on Friday, November 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, GSK has an average rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.58).

Insider Activity at GSK

In related news, insider Jonathan Symonds purchased 1,500 shares of GSK stock in a transaction on Friday, December 20th. The shares were bought at an average cost of GBX 1,315 ($16.44) per share, for a total transaction of £19,725 ($24,659.33). 1.61% of the stock is owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.